scholarly journals The Changing Face of Young-Onset Diabetes: Type 1 Optimism Mellowed by Type 2 Concerns

Diabetes Care ◽  
2013 ◽  
Vol 36 (12) ◽  
pp. 3857-3859 ◽  
Author(s):  
T. J. Orchard
Keyword(s):  
Diabetes Type ◽  
Diabetes Type 1 ◽  
Young Onset ◽  
Onset Diabetes

scholarly journals Long-Term Complications and Mortality in Young-Onset Diabetes: Type 2 diabetes is more hazardous and lethal than type 1 diabetes

Diabetes Care ◽  
2013 ◽  
Vol 36 (12) ◽  
pp. 3863-3869 ◽  
Author(s):  
M. I. Constantino ◽  
L. Molyneaux ◽  
F. Limacher-Gisler ◽  
A. Al-Saeed ◽  
C. Luo ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Young Onset ◽  
Onset Diabetes ◽  
Complications And Mortality

scholarly journals Homocysteinemia as a risk factor of diabetic nephropathy in children and adolescents

2008 ◽  
Vol 14 (4) ◽  
pp. 320-323
Author(s):  
Zh. V. Shutskaya
Keyword(s):  
Risk Factor ◽  
Diabetic Nephropathy ◽  
Children And Adolescents ◽  
Independent Risk Factor ◽  
Diabetes Type ◽  
Diabetes Type 1

This article summarizes data on homocysteinemia and its influence on vascular pathologic changes in patients with different diseases including diabetes type 1 and type 2. The role of homocystein as an independent risk factor for diabetic nephropathy in children and adolescents is discussed. The problem of homocysteinemia treatment is reviewed.

scholarly journals Midterm Fate of the Contralateral Foot in Charcot Arthropathy

2020 ◽  
Vol 41 (10) ◽  
pp. 1181-1189
Author(s):  
Felix W. A. Waibel ◽  
Martin C. Berli ◽  
Viviane Gratwohl ◽  
Kati Sairanen ◽  
Dominik Kaiser ◽  
...  
Keyword(s):  
Diabetes Type 2 ◽  
Female Gender ◽  
Major Amputation ◽  
Diabetes Type ◽  
Diabetes Type 1 ◽  
Charcot Arthropathy ◽  
Level Of Evidence ◽  
Patients With Diabetes

Background: The contralateral foot in Charcot arthropathy or neuroarthropathy (CN) is subject to increased plantar pressure. To date, the clinical consequences of this pressure elevation are yet to be determined. The aim of this study was to evaluate ulcer and amputation rates of the contralateral foot in CN. Methods: We abstracted the medical records of 130 consecutive subjects with unilateral CN. Rates of contralateral CN development and recurrence, contralateral ulcer development, and contralateral amputations were recorded. Statistical analysis was performed to identify possible risk factors for contralateral CN and ulcer development, and contralateral amputation. Mean follow-up was 6.2 (SD 4) years. Results: After a mean of 2.5 years, 19.2% patients developed contralateral CN. Female gender was associated with contralateral CN development (odds ratio 3.13, 95% confidence interval 1.27, 7.7). Overall, 46.2% patients developed a contralateral ulcer. Among the patients who developed contralateral CN, 60% developed an ulcer. Sanders type 2 at the index foot (midfoot CN) was significantly associated with contralateral ulcer development. Ulcer-free survival (UFS) differed significantly between patients with diabetes type 1 (median UFS 5131 days) and patients with diabetes type 2 (median UFS 2158 days). A total of 25 amputations had to be performed in 22 (16.9%) patients. Three of those 22 patients (2.3%) needed major amputation. Conclusion: Almost 20% of patients developed contralateral CN. Nearly half of people with CN developed a contralateral foot ulceration. Patients with type 2 diabetes had significantly shorter UFS than patients with diabetes type 1. Every sixth patient needed an amputation, with the majority being minor amputations. The contralateral foot should be monitored closely and included in the treatment in patients with CN. Level of Evidence: Level IV, retrospective study.

Methylglyoxal and Advanced Glycation End Products in Patients with Diabetes – What We Know so Far and the Missing Links

2017 ◽  
Vol 127 (08) ◽  
pp. 497-504 ◽  
Author(s):  
Jan Benedikt Groener ◽  
Dimitrios Oikonomou ◽  
Ruan Cheko ◽  
Zoltan Kender ◽  
Johanna Zemva ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Absolute Risk ◽  
Diabetes Type ◽  
Diabetes Type 1 ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Patients With Diabetes

AbstractHyperglycemia explains the development of late diabetic complications in patients with diabetes type 1 and type 2 only partially. Most therapeutic efforts relying on intensive glucose control failed to decrease the absolute risk for complications by more than 10%, especially in patients with diabetes type 2. Therefore, alternative pathophysiological pathways have to be examined, in order to develop more individualized treatment options for patients with diabetes in the future. One such pathway might be the metabolism of dicarbonyls, among them methylglyoxal and the accumulation of advanced glycation end products. Here we review currently available epidemiological data on dicarbonyls and AGEs in association with human diabetes type 1 and type 2.

P612: Small and large fibre neuropathy in patients with diabetes type 1 compared with type 2: a follow-up study

2014 ◽  
Vol 125 ◽  
pp. S215
Author(s):  
S. Løseth ◽  
E. Stålberg ◽  
S. Lindal ◽  
R. Jorde ◽  
S.I. Mellgren
Keyword(s):  
Diabetes Type ◽  
Diabetes Type 1 ◽  
Follow Up Study ◽  
Patients With Diabetes ◽  
Large Fibre
Sign in / Sign up

Export Citation Format

Share Document